Logo for Applied Therapeutics Inc

Applied Therapeutics Investor Relations Material

Latest events

Logo for Applied Therapeutics Inc

Study Result

Applied Therapeutics
Logo for Applied Therapeutics

Q3 2024

7 Nov, 2024
Logo for Applied Therapeutics

Q2 2024

7 Aug, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from Applied Therapeutics Inc

Access all reports
Applied Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in discovering and developing innovative drugs for conditions with significant unmet medical needs. The company focuses on novel drug candidates targeting validated molecular pathways in diseases such as Galactosemia, Diabetic Cardiomyopathy, Diabetic Peripheral Neuropathy, and other areas with high unmet medical needs. Among its pipeline, notable drug candidates include AT-001, an aldose reductase inhibitor for diabetic complications; AT-007 for rare diseases such as SORD Deficiency; and AT-003, designed for diabetic retinopathy. Additionally, Applied Therapeutics is exploring AT-104, a PI3K inhibitor for orphan hematological oncology, specifically T Cell Acute Lymphoblastic Leukaemia. Applied Therapeutics is headquartered in New York, NY, and its shares are listed on the NASDAQ.